In a new study by University of Kentucky Markey Cancer Center researchers have suggested that targeting a key enzyme and its associated metabolic programming may lead to novel drug development to treat the disease.
The study collected metabolic data directly from more than 120 human lung cancer patients. UK's Center for Environmental and Systems Biochemistry (CESB) researchers measured the in situ activity of the two enzymes in patients with early stage lung cancer. When they infused the patients with a glucose tagged with stable heavy atoms immediately prior to surgical removal of tumor tissue, they found that PC was selectively activated - in other words, PC expression may play an important role in the development of lung cancer.
The study is published in the Journal of Clinical Investigation.